Efficacy and Safety of Tolvaptan for Patients With Autosomal Dominant Polycystic Kidney Disease in Real-world Practice: A Single Institution Retrospective Study
In Vivo · 2023
DOI: 10.21873/invivo.13144 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2023. Verfasst von Hiroshi Masuda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chiba Rousai Hospital, Chiba, Japan; hrsmasuda@yahoo.co.jp. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Chiba Rousai Hospital, Chiba, Japan; hrsmasuda@yahoo.co.jp.
- Department of Urology, Teikyo University Chiba Medical Center, Chiba, Japan.
Zitieren
APA
Masuda, H., Shimizu, N., Sekine, K., Okato, A., Hou, K., Suyama, T., Araki, K., Kojima, S., & Naya, Y. (2023). Efficacy and Safety of Tolvaptan for Patients With Autosomal Dominant Polycystic Kidney Disease in Real-world Practice: A Single Institution Retrospective Study. In Vivo. https://doi.org/10.21873/invivo.13144
Vancouver
Masuda H, Shimizu N, Sekine K, Okato A, Hou K, Suyama T, et al. Efficacy and Safety of Tolvaptan for Patients With Autosomal Dominant Polycystic Kidney Disease in Real-world Practice: A Single Institution Retrospective Study. In Vivo. 2023. doi:10.21873/invivo.13144
BibTeX
@article{Masuda2023,
author = {Masuda, Hiroshi and Shimizu, Nobuhiko and Sekine, Keita and Okato, Atsushi and Hou, Kyokusin and Suyama, Takahito and Araki, Kazuhiro and Kojima, Satoko and Naya, Yukio},
title = {Efficacy and Safety of Tolvaptan for Patients With Autosomal Dominant Polycystic Kidney Disease in Real-world Practice: A Single Institution Retrospective Study},
journal = {In Vivo},
year = {2023},
doi = {10.21873/invivo.13144}
}
EUVIMED